
    
      This is a exploratory, single-arm, open-label trial. The investigator's primary purpose is to
      compare that ORR of patients with camrelizumab plus apatinib and POF for advanced/metastatic
      gastric cancer.

      In treatment period, patients will be administrated camrelizumab plus apatinib and POF, every
      28 days for 1 cycle, until disease progression, toxicity intolerance, withdrawal of informed
      consent, patients judged must be terminated study termination.

      The imaging evaluation was performed according to the RECIST 1.1 criteria every 8 weeks.
    
  